Aspartyl-alanyl-diketopiperazine
Trade name: Ampion
Small moleculeexperimental
Clinical trial activity
14 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
10
Phase 3
7
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01839331)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Immunomodulation
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1NC(=O)[C@H](CC(=O)O)NC1=O- Mol. weight
- 186.17 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297349 ↗
Also known as
- ampion
- ampion
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04880161 | Phase 1 | May 31, 2021 | Ampio Pharmaceuticals. Inc. |
| NCT04839965 | Phase 2 | May 31, 2021 | Ampio Pharmaceuticals. Inc. |
| NCT04868890 | Phase 2 | Apr 30, 2021 | Ampio Pharmaceuticals. Inc. |
| NCT04606784 | Phase 1 | Oct 28, 2020 | Ampio Pharmaceuticals. Inc. |
| NCT04456452 | Phase 1 | Jul 27, 2020 | Ampio Pharmaceuticals. Inc. |
| NCT03988023 | Phase 3 | Jun 24, 2019 | Ampio Pharmaceuticals. Inc. |
| NCT03349645 | Phase 3 | Dec 8, 2017 | Ampio Pharmaceuticals. Inc. |
| NCT03182686 | Phase 3 | Jun 19, 2017 | Ampio Pharmaceuticals. Inc. |
| NCT02762760 | Phase 1 | May 1, 2016 | Ampio Pharmaceuticals. Inc. |
| NCT02556710 | Phase 3 | Sep 1, 2015 | Ampio Pharmaceuticals. Inc. |
| NCT02242435 | Phase 3 | Sep 1, 2014 | Ampio Pharmaceuticals. Inc. |
| NCT02184156 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Ampio Pharmaceuticals. Inc. |
| NCT02024529 | Phase 3 | Dec 1, 2013 | Ampio Pharmaceuticals. Inc. |
| NCT01839331 | Phase 3 | Mar 1, 2013 | Ampio Pharmaceuticals. Inc. |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ampio Pharmaceuticals. Inc. | For profit | 14 | 14 | 3 | 2013 |
1 organizations
Page 1 / 1